From the Research
Sermorelin is a growth hormone releasing hormone (GHRH) analog that should be used in adult longevity medicine and functional medicine with caution, under the guidance of a healthcare provider experienced with peptide therapies, and with careful monitoring of its effects on morbidity, mortality, and quality of life. The typical dosing regimen for Sermorelin is 200-500 mcg administered subcutaneously daily, usually before bedtime to align with the body's natural growth hormone pulse, as supported by recent studies 1, 2. For optimal results, most practitioners recommend cycling the medication with 5-6 days on and 1-2 days off, or 3 months on and 1 month off, to prevent receptor desensitization. Monitoring should include baseline and periodic blood tests for IGF-1, fasting glucose, hemoglobin A1c, and thyroid function, as changes in these parameters can indicate the efficacy and safety of the treatment 3, 4. Common side effects of Sermorelin include injection site reactions, headache, and flushing, which typically resolve with continued use. More serious risks include insulin resistance, edema, joint pain, and potential theoretical concerns about promoting growth of pre-existing cancers, though clinical evidence for this is limited 5, 2. Sermorelin works by binding to GHRH receptors in the pituitary gland, stimulating the natural production and release of growth hormone rather than directly supplying it. This approach may offer a more physiologic pattern of growth hormone release compared to direct growth hormone administration. Benefits typically reported with Sermorelin use include improved sleep quality, increased lean muscle mass, reduced body fat, enhanced recovery from exercise, improved skin elasticity, and potentially improved cognitive function, as noted in studies on growth hormone therapy 1, 2. Results typically begin to appear after 3-6 months of consistent use. It is essential to weigh the potential benefits of Sermorelin against its risks and to carefully monitor patients for any adverse effects, particularly given the concerns about insulin resistance and potential impacts on cardiovascular risk 4.